Toxoplasmose

Toxoplasmosis denotes an infection caused by the protozoan parasite Toxoplasma gondii, which traditionally has been monitored for congenital transmission and severe manifestations in immunocompromised populations ^[3][2]. The organism exhibits a strong predilection for neural and retinal tissues, where it frequently establishes a latent phase capable of reactivation rather than relying solely on acute reinfection ^[1]. Contemporary assessments increasingly link chronic latent infection to diverse neuropsychiatric associations, substantially elevating its recognized public health significance beyond overt acute morbidity ^[2].

Central nervous system involvement predominantly emerges from the reactivation of latent tissue cysts within the brain, particularly among individuals with advanced immune deficiency ^[1]. Congenital acquisition frequently precipitates severe neurological impairment and structural ocular damage in developing fetuses, whereas chronic maternal infection has been correlated with long-term psychiatric disturbances ^[3]. Postnatally acquired presentations typically manifest as retinochoroiditis, serving as a primary infectious etiology for posterior uveitis and necessitating characteristic clinical recognition alongside serologic evaluation ^[4].

The infection demonstrates pronounced regional variation, exhibiting elevated prevalence rates in areas characterized by substantial HIV burdens and restricted antiretroviral access ^[1]. Additionally, the disease maintains a consistent community-level presence as a leading infectious cause of posterior uveitis, reflecting its enduring global distribution across diverse populations ^[4].

Primary acquisition occurs through the ingestion of contaminated food and water, alongside direct contact with environmental reservoirs such as infected soil ^[3]. Vertical transmission from mother to fetus constitutes another critical propagation pathway, capable of initiating severe developmental pathology during gestation ^[3]. These distinct exposure routes highlight the necessity of environmental hygiene and prenatal monitoring to interrupt established transmission cycles ^[3].

Preventive approaches for this infection currently lack approved human vaccines, as ongoing prophylactic trials remain restricted to animal models without confirmed efficacy or safety for clinical application ^[1]. Consequently, mitigation strategies emphasize early diagnostic confirmation via combined serological, imaging, and symptomatic evaluation to enable prompt therapeutic intervention ^[1]. Sustained public health control will ultimately depend on validating safe immunization platforms and refining standardized diagnostic criteria to limit disease progression ^[1].

1. 1 Dian S et al. Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog Glob Health. 2023 Feb. PMID: 35694771. doi: 10.1080/20477724.2022.2083977. PubMed: https://pubmed.ncbi.nlm.nih.gov/35694771/
2. 2 Milne G et al. Toxoplasma gondii: AnUnderestimated Threat? Trends Parasitol. 2020 Dec. PMID: 33012669. doi: 10.1016/j.pt.2020.08.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/33012669/
3. 3 Deganich M et al. Toxoplasmosis Infection during Pregnancy. Trop Med Infect Dis. 2022 Dec 21. PMID: 36668910. doi: 10.3390/tropicalmed8010003. PubMed: https://pubmed.ncbi.nlm.nih.gov/36668910/
4. 4 Kalogeropoulos D et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022 Jan. PMID: 34370174. doi: 10.1007/s10792-021-01994-9. PubMed: https://pubmed.ncbi.nlm.nih.gov/34370174/